Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $17.64B, up 21.3% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $17.64B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.64B | +21.3% |
| FY2024 | Dec 31, 2024 | $14.54B | +48.9% |
| FY2023 | Dec 31, 2023 | $9.77B | +22.9% |
| FY2022 | Dec 31, 2022 | $7.95B | -21.0% |
| FY2021 | Dec 31, 2021 | $10.06B | -0.9% |
| FY2020 | Dec 31, 2020 | $10.15B | +11.7% |
| FY2019 | Dec 31, 2019 | $9.09B | +8.1% |
| FY2018 | Dec 31, 2018 | $8.40B | -3.4% |
| FY2017 | Dec 31, 2017 | $8.70B | +5.2% |
| FY2016 | Dec 31, 2016 | $8.27B | -7.9% |
| FY2015 | Dec 31, 2015 | $8.98B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.75B | +113.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.86B | +39.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.01B | +70.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.81B | +5.4% |
| Q2 FY2022 | Jun 30, 2022 | $2.23B | -8.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.48B | +52.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.35B | – |
| Q2 FY2019 | Jun 30, 2019 | $2.66B | – |
| Q2 FY2018 | Jun 30, 2018 | $2.43B | – |
| Q2 FY2017 | Jun 30, 2017 | $2.28B | – |
See a number that looks wrong?